是否是腫瘤細(xì)胞：1
物種來源：人
生長(zhǎng)狀態(tài)：混合型生長(zhǎng)
器官來源：乳房
運(yùn)輸方式：凍存運(yùn)輸
ATCC Number：CRL-2330?
數(shù)量：大量
相關(guān)疾?。浩渌膊?br />
細(xì)胞形態(tài)：上皮樣
年限：TNM stage IV, grade 3
規(guī)格：40 ul Designations: HCC1569
Depositors: ?AF Gazdar, AK Virmani
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:mixed adherent-suspension
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: mammary gland; breast
Tumor Stage: TNM stage IV, grade 3
Disease: primary metaplastic carcinoma
Cellular Products:Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Applications:The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay.
The cells are poorly differentiated.
The cells are positive for expression of Her2-neu and negative for expression of p53.
HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cell line is derived from an older patient with a germline mutation in the FHIT gene.
Receptors:estrogen receptor, negative
progesterone receptor, negative
Oncogene:her2/neu +, p53 -
Cytogenetic Analysis:polyploid
Age: 70
Gender: female
Ethnicity: Black
Comments:This cell line was initiated on 3/8/95 and took 19 months to establish.
The patient received prior chemotherapy and had no family history of breast cancer. The tumor was classified as TNM stage IV, grade 3, metaplastic carcinoma with 4 out of 18 lymph node metastasis.
The cells are poorly differentiated.
The cells are positive for expression of Her2-neu and negative for expression of p53.
HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay.
The cell line is derived from an older patient with a germline mutation in the FHIT gene. The FHIT gene is located at 3p14.2 and the mutation is a transversion at nucleotide 651 (G to T).The patient's daughter carries the same gene mutation.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Protocol:
- Remove culture medium to a centrifuge tube.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
- Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually with 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- To remove trypsin-EDTA solution, transfer cell suspension to the centrifuge tube with the medium and cells from step #1 and spin at approximately 125 xg for 5 to 10 minutes.
- Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels.
- Place culture vessels in incubators at 37?C.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 32258: Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768
38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
